Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancers. The company's lead compound is COTI-2, a clinical stage small molecule targeting p53 proteins, as well as is in the Phase I clinical trial for the treatment of gynecologic cancers, and head and neck squamous cell carcinoma. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:COTQF
CUSIPN/A
Phone519-858-5157
Debt
Debt-to-Equity RatioN/A
Current Ratio0.39
Quick Ratio0.39
Price-To-Earnings
Trailing P/E Ratio-1.19
Forward P/E Ratio-1.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book12.66
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-4,710,000.00
Net MarginsN/A
Return on Equity-1,166.33%
Return on Assets-182.57%
Miscellaneous
EmployeesN/A
Outstanding Shares16,700,000
Market Cap$6.34 million
Cotinga Pharmaceuticals (OTCMKTS:COTQF) Frequently Asked Questions
What is Cotinga Pharmaceuticals' stock symbol?
Cotinga Pharmaceuticals trades on the OTCMKTS under the ticker symbol "COTQF."
How were Cotinga Pharmaceuticals' earnings last quarter?
When is Cotinga Pharmaceuticals' next earnings date?
Who are some of Cotinga Pharmaceuticals' key competitors?
Some companies that are related to Cotinga Pharmaceuticals include Nemus Bioscience (NMUS), RegeneRx Biopharmaceuticals (RGRX), X T L Biopharmaceuticals (XTLB), Soligenix, Inc. Common Stock (SNGX), Pernix Therapeutics (PTX), Akari Therapeutics (AKTX), Eyegate Pharmaceuticals (EYEG), Regulus Therapeutics (RGLS), Adial Pharmaceuticals (ADIL), Egalet (EGLT), Fibrocell Science (FCSC), Catabasis Pharmaceuticals (CATB), Prana Biotechnology (PRAN), Cyclacel Pharmaceuticals (CYCC) and Acasti Pharma (ACST).
Who are Cotinga Pharmaceuticals' key executives?
Cotinga Pharmaceuticals' management team includes the folowing people:
- Ms. Alison D. Silva, Chief Exec. Officer, Pres and Director
- Mr. Eugene Francis Kelly, Chief Financial Officer
- Ms. Debi Sanderson MBA, Director of Resourcing & Operations
- Dr. Richard T. Ho, Chief Scientific Officer (Age 55)
- Mr. Paul Papi, VP of Investor Relations
Has Cotinga Pharmaceuticals been receiving favorable news coverage?
News coverage about COTQF stock has trended somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cotinga Pharmaceuticals earned a news and rumor sentiment score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 45.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Cotinga Pharmaceuticals.
How do I buy shares of Cotinga Pharmaceuticals?
Shares of COTQF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cotinga Pharmaceuticals' stock price today?
One share of COTQF stock can currently be purchased for approximately $0.3799.
How big of a company is Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals has a market capitalization of $6.34 million. The company earns $-4,710,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.
How can I contact Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals' mailing address is 700 Collip Circle Suite 213, London A6, N6G 4X8. The company can be reached via phone at 519-858-5157 or via email at [email protected]
MarketBeat Community Rating for Cotinga Pharmaceuticals (OTCMKTS COTQF)
MarketBeat's community ratings are surveys of what our community members think about Cotinga Pharmaceuticals and other stocks. Vote "Outperform" if you believe COTQF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COTQF will underperform the S&P 500 over the long term. You may vote once every thirty days.
